A Noninvasive Comparison Study between Human Gliomas with IDH1 and IDH2 Mutations by MR Spectroscopy

The oncogenes that are expressed in gliomas reprogram particular pathways of glucose, amino acids, and fatty acid metabolism. Mutations in isocitrate dehydrogenase genes (IDH1/2) in diffuse gliomas are associated with abnormally high levels of 2-hydroxyglutarate (2-HG) levels. The aim of this study was to determine whether metabolic reprogramming associated with IDH mutant gliomas leads to additional 1H MRS-detectable differences between IDH1 and IDH2 mutations, and to identify metabolites correlated with 2-HG. A total of 21 glioma patients (age= 37 ± 11, 13 males) were recruited for magnetic resonance spectroscopy (MRS) using semi-localization by adiabatic selective refocusing pulse sequence at an ultra-high-field (7T). For 20 patients, the tumor mutation subtype was confirmed by immunohistochemistry and DNA sequencing. LCModel analysis was applied for metabolite quantification. A two-sample t-test was used for metabolite comparisons between IDH1 (n = 15) and IDH2 (n = 5) mutant gliomas. The Pearson correlation coefficients between 2-HG and associated metabolites were calculated. A Bonferroni correction was applied for multiple comparison. IDH2 mutant gliomas have a higher level of 2-HG/tCho (total choline=phosphocholine+glycerylphosphorylcholine) (2.48 ± 1.01vs.0.72 ± 0.38, Pc < 0.001) and myo-Inositol/tCho (2.70 ± 0.90 vs. 1.46 ± 0.51, Pc = 0.011) compared to IDH1 mutation gliomas. Associated metabolites, myo-Inositol and glucose+taurine were correlated with 2-HG levels. These results show the improved characterization of the metabolic pathways in IDH1 and IDH2 gliomas for precision medicine.

[1]  M. Julià-Sapé,et al.  Cancer metabolism in a snapshot: MRS(I) , 2019, NMR in biomedicine.

[2]  A. Iafrate,et al.  Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate , 2018, Nature Communications.

[3]  P. Vyas,et al.  Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. , 2017, Blood.

[4]  Susan M. Chang,et al.  Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma , 2017, Scientific Reports.

[5]  T. Itoh,et al.  Myo-inositol concentration in MR spectroscopy for differentiating high grade glioma from primary central nervous system lymphoma , 2017, Journal of Neuro-Oncology.

[6]  S. Venneti,et al.  Non-invasive metabolic imaging of brain tumours in the era of precision medicine , 2016, Nature Reviews Clinical Oncology.

[7]  Klaus Scheffler,et al.  MR spectroscopy for in vivo assessment of the oncometabolite 2‐hydroxyglutarate and its effects on cellular metabolism in human brain gliomas at 9.4T , 2016, Journal of magnetic resonance imaging : JMRI.

[8]  N. Voets,et al.  Improved Localization for 2-Hydroxyglutarate Detection at 3 T Using Long-TE Semi-LASER , 2016, Tomography.

[9]  Haoyuan Wang,et al.  The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas , 2016, Journal of experimental & clinical cancer research : CR.

[10]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[11]  Roland Kreis,et al.  The trouble with quality filtering based on relative Cramér‐Rao lower bounds , 2016, Magnetic resonance in medicine.

[12]  Peter Jezzard,et al.  Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations. , 2016, Cancer research.

[13]  B. Rosen,et al.  Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate , 2015, Clinical Cancer Research.

[14]  Christian M. Metallo,et al.  Metabolic consequences of oncogenic IDH mutations. , 2015, Pharmacology & therapeutics.

[15]  E. Gottlieb,et al.  Research into cancer metabolomics: Towards a clinical metamorphosis. , 2015, Seminars in cell & developmental biology.

[16]  R. Macaulay Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas. , 2015, Cancer control : journal of the Moffitt Cancer Center.

[17]  T. Scheenen,et al.  Multi‐center reproducibility of neurochemical profiles in the human brain at 7 T , 2015, NMR in biomedicine.

[18]  L. Staudt,et al.  IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. , 2014, Blood.

[19]  J. Stebbing,et al.  IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. , 2013, Future oncology.

[20]  W. Yung,et al.  IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. , 2013, Neuro-oncology.

[21]  O. Abdel-Wahab,et al.  The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular Compartmentalization* , 2012, The Journal of Biological Chemistry.

[22]  Hui Yang,et al.  IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives , 2012, Clinical Cancer Research.

[23]  W. Teeuwisse,et al.  Simulations of high permittivity materials for 7 T neuroimaging and evaluation of a new barium titanate‐based dielectric , 2012, Magnetic resonance in medicine.

[24]  Ovidiu C. Andronesi,et al.  Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy , 2012, Science Translational Medicine.

[25]  Dinesh Rakheja,et al.  2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients , 2011, Nature Medicine.

[26]  Hong Wu,et al.  Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy , 2012, Journal of Neuro-Oncology.

[27]  R. Hills,et al.  The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. , 2011, Blood.

[28]  H. Dombret,et al.  Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. , 2011, Blood.

[29]  Hai Yan,et al.  2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations , 2011, PloS one.

[30]  K. Kinzler,et al.  Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome , 2011, Proceedings of the National Academy of Sciences.

[31]  A. Iafrate,et al.  A Sensitive and Specific Diagnostic Panel to Distinguish Diffuse Astrocytoma From Astrocytosis: Chromosome 7 Gain With Mutant Isocitrate Dehydrogenase 1 and p53 , 2011, Journal of neuropathology and experimental neurology.

[32]  M. Caligiuri,et al.  IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[34]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[35]  R Gruetter,et al.  Field mapping without reference scan using asymmetric echo‐planar techniques , 2000, Magnetic resonance in medicine.